2031 年までの北米薬物動態サービス市場予測 - 地域別分析 - 薬物タイプ別 (低分子、高分子、ワクチン)、サービス タイプ別 (前臨床 ADME およびヒト研究、PK/PD 分析およびレポート、投与シミュレーション、リスク分析など)、治療用途別 (腫瘍学、感染症、神経疾患、自己免疫疾患、婦人科疾患、心血管疾患、呼吸器疾患など)、エンド ユーザー別 (製薬およびバイオテクノロジー企業、契約研究機関など)
薬物動態研究の適用範囲の拡大が北米の薬物動態サービス市場を牽引
薬物動態研究は、ヒト等価用量（HED）レベル、無影響量（NOEL）、薬物動態/薬力学試験など、いくつかのパラメータを決定するために採用されています。実施される前臨床プログラムの主な焦点は、薬物動態研究での試験のための安全で効果的な用量範囲の分析をサポートすることです。いくつかの毒物学研究では、NOEL、つまり副作用を引き起こさない最高用量に関するデータが実施されました。臨床薬物動態データが不足している場合は、この投与量レベルは、比較体表面積ベースで HED レベルにさらに変換されます。潜在的な薬物候補の薬物動態プロファイルを理解することは、創薬プログラムで重要な役割を果たします。規制当局は、薬物動態研究の実施を推進する上で大きな役割を果たします。これらの研究は、入院患者に提供される薬剤ケア サービスの最適化にも役立ちます。PK モデルは、薬物への曝露、薬物の濃度を決定して最適な投与量を分析したり、人体における薬物の配置を分析するためによく適用されます。医療提供者は、PK の原則を実装して、薬物濃度、一部の薬物の投与量を設計し、意図した治療結果を最大化し、毒性を最小限に抑えます。
北米薬物動態サービス市場の概要
米国は、北米の薬物動態サービス市場で最大のシェアを占めています。この国は主要な臨床研究の目的地として浮上しており、世界で実施される臨床試験全体の約 50% を占めています。確立された医療インフラ、迅速な承認タイムライン、および有利な規制枠組みが利用可能であることから、製薬研究会社が臨床試験を実施するための環境が整っています。さらに、米国で実施された試験で生成されたデータは世界的に受け入れられています。世界保健機関（WHO）のレポートによると、2021年に米国は最も多くの臨床試験（157,618）を登録しました。
北米の薬物動態サービス市場の収益と2031年までの予測（百万米ドル）
北米の薬物動態サービス市場のセグメンテーション
北米の薬物動態サービス市場は、薬物タイプ、サービスタイプ、治療アプリケーション、エンドユーザー、および国に分類されています。
薬物タイプに基づいて、北米の薬物動態サービス市場は、小分子、大分子、およびワクチンに分割されています。 2023年には、小分子セグメントが最大の市場シェアを占めました。
サービスタイプ別に見ると、北米の薬物動態サービス市場は、前臨床ADMEおよびヒト研究、PK / PD分析およびレポート、投与シミュレーション、リスク分析などに分類されています。前臨床ADMEおよびヒト研究セグメントは、2023年に最大の市場シェアを占めました。
治療用途別に見ると、北米の薬物動態サービス市場は、腫瘍学、感染症、神経疾患、自己免疫疾患、婦人科疾患、心血管疾患、呼吸器疾患などに分類されています。腫瘍学セグメントは、2023年に最大の市場シェアを占めました。
エンドユーザー別に見ると、北米の薬物動態サービス市場は、製薬およびバイオテクノロジー企業、契約研究機関、その他に分類されています。 2023年には、契約研究機関セグメントが最大の市場シェアを占めました。
国別に見ると、北米の薬物動態サービス市場は、米国、カナダ、メキシコに分かれています。2023年には、米国が北米の薬物動態サービス市場シェアを独占しました。
Charles River Laboratories International Inc、Eurofins Scientific SE、Evotec SE、Certara Inc.、Parexel International Corp、Thermo Fisher Scientific Inc.、Allucent、PACIFIC BIOLABS、SGS SAは、北米の薬物動態サービス市場で事業を展開している大手企業の一部です。
TABLE OF CONTENTS
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Pharmacokinetics Services Market Landscape
4.1 PEST Analysis
5. North America Pharmacokinetics Services Market - Key Market Dynamics
5.1 Market Drivers
5.1.1 Rising Prevalence of Chronic and Infectious Diseases
5.1.2 Expanding Range of Application of Pharmacokinetic Studies
5.1.3 Outsourcing of Pharmacokinetics Services to CROs
5.2 Market Restraints
5.2.1 Limited Reach of Pharmacokinetics Service Providers in Emerging Countries
5.3 Market Opportunities
5.3.1 Increasing Adoption of In-Vivo and In-Vitro Models for Understanding Variability in Pharmacokinetics
5.4 Future Trend
5.4.1 Increasing Adoption of Big Data Analytics in Pharmacokinetics Services
5.5 Impact of Drivers and Restraints:
6. Pharmacokinetics Services Market - North America Analysis
6.1 North America Pharmacokinetics Services Market Revenue (US$ Million), 2021-2031
7. North America Pharmacokinetics Services Market Analysis - by Drug Type
7.1 Overview
7.2 Small Molecule
7.2.1 Overview
7.2.2 Small Molecule: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
7.3 Large Molecule
7.3.1 Overview
7.3.2 Large Molecule: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
7.4 Vaccines
7.4.1 Overview
7.4.2 Vaccines: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8. North America Pharmacokinetics Services Market Analysis - by Service Type
8.1 Overview
8.2 Pre-Clinical ADME and Human Studies
8.2.1 Overview
8.2.2 Pre-Clinical ADME and Human Studies: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.3 PK/PD Analysis and Reporting
8.3.1 Overview
8.3.2 PK/PD Analysis and Reporting: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.4 Dosing Simulations
8.4.1 Overview
8.4.2 Dosing Simulations: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.5 Risk Analysis
8.5.1 Overview
8.5.2 Risk Analysis: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.6 Others
8.6.1 Overview
8.6.2 Others: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9. North America Pharmacokinetics Services Market Analysis - by Therapeutic Application
9.1 Oncology
9.1.1 Overview
9.1.2 Oncology: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9.2 Infectious Diseases
9.2.1 Overview
9.2.2 Infectious Diseases: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9.3 Neurological Disorders
9.3.1 Overview
9.3.2 Neurological Disorders: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9.4 Autoimmune Diseases
9.4.1 Overview
9.4.2 Autoimmune Diseases: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9.5 Gynecological Disorders
9.5.1 Overview
9.5.2 Gynecological Disorders: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9.6 Cardiovascular Diseases
9.6.1 Overview
9.6.2 Cardiovascular Diseases: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9.7 Respiratory Disorders
9.7.1 Overview
9.7.2 Respiratory Disorders: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9.8 Others
9.8.1 Overview
9.8.2 Others: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10. North America Pharmacokinetics Services Market Analysis - by End User
10.1 Pharmaceutical and Biotechnology Companies
10.1.1 Overview
10.1.2 Pharmaceutical and Biotechnology Companies: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.2 Contract Research Organization
10.2.1 Overview
10.2.2 Contract Research Organization: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.3 Others
10.3.1 Overview
10.3.2 Others: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
11. North America Pharmacokinetics Services Market - Country Analysis
11.1 North America
11.1.1 North America Pharmacokinetics Services Market Breakdown, by Key Countries, 2023 and 2031 (%)
11.1.1.1 United States: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
11.1.1.1.1 Overview
11.1.1.1.2 United States: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
11.1.1.1.3 United States: North America Pharmacokinetics Services Market Breakdown, by Drug Type
11.1.1.1.4 United States: North America Pharmacokinetics Services Market Breakdown, by Service Type
11.1.1.1.5 United States: North America Pharmacokinetics Services Market Breakdown, by Therapeutic Application
11.1.1.1.6 United States: North America Pharmacokinetics Services Market Breakdown, by End User
11.1.1.2 Canada: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
11.1.1.2.1 Overview
11.1.1.2.2 Canada: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
11.1.1.2.3 Canada: North America Pharmacokinetics Services Market Breakdown, by Drug Type
11.1.1.2.4 Canada: North America Pharmacokinetics Services Market Breakdown, by Service Type
11.1.1.2.5 Canada: North America Pharmacokinetics Services Market Breakdown, by Therapeutic Application
11.1.1.2.6 Canada: North America Pharmacokinetics Services Market Breakdown, by End User
11.1.1.3 Mexico: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
11.1.1.3.1 Overview
11.1.1.3.2 Mexico: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
11.1.1.3.3 Mexico: North America Pharmacokinetics Services Market Breakdown, by Drug Type
11.1.1.3.4 Mexico: North America Pharmacokinetics Services Market Breakdown, by Service Type
11.1.1.3.5 Mexico: North America Pharmacokinetics Services Market Breakdown, by Therapeutic Application
11.1.1.3.6 Mexico: North America Pharmacokinetics Services Market Breakdown, by End User
12. Company Profile
12.1 Charles River Laboratories International Inc
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Eurofins Scientific SE
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Evotec SE
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Certara Inc.
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.5 Parexel International Corp
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Thermo Fisher Scientific Inc.
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Allucent
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 PACIFIC BIOLABS
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 SGS SA
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
13. Appendix
13.1 About The Insight Partners
13.2 Glossary of Terms for Pharmacokinetic Services Market
List of Tables
Table 1. North America Pharmacokinetics Services Market Segmentation
Table 2. United States: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type
Table 3. United States: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type
Table 4. United States: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application
Table 5. United States: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User
Table 6. Canada: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type
Table 7. Canada: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type
Table 8. Canada: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application
Table 9. Canada: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User
Table 10. Mexico: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type
Table 11. Mexico: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type
Table 12. Mexico: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application
Table 13. Mexico: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User
Table 14. Glossary of Terms
List of Figures
Figure 1. North America Pharmacokinetics Services Market Segmentation, by Country
Figure 2. PEST Analysis
Figure 3. North America Pharmacokinetics Services Market - Key Market Dynamics
Figure 4. Impact Analysis of Drivers and Restraints
Figure 5. North America Pharmacokinetics Services Market Revenue (US$ Million), 2021-2031
Figure 6. North America Pharmacokinetics Services Market Share (%) - by Drug Type (2023 and 2031)
Figure 7. Small Molecule: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 8. Large Molecule: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 9. Vaccines: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 10. North America Pharmacokinetics Services Market Share (%) - by Service Type (2023 and 2031)
Figure 11. Pre-Clinical ADME and Human Studies: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 12. PK/PD Analysis and Reporting: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 13. Dosing Simulations: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 14. Risk Analysis: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 15. Others: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 16. North America Pharmacokinetics Services Market Share (%) - by Therapeutic Application (2023 and 2031)
Figure 17. Oncology: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 18. Infectious Diseases: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 19. Neurological Disorders: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 20. Autoimmune Diseases: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 21. Gynecological Disorders: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 22. Cardiovascular Diseases: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 23. Respiratory Disorders: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 24. Others: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 25. North America Pharmacokinetics Services Market Share (%) - by End User (2023 and 2031)
Figure 26. Pharmaceutical and Biotechnology Companies: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 27. Contract Research Organization: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 28. Others: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 29. North America Pharmacokinetics Services Market by Key Countries - Revenue (2023) (US$ Million)
Figure 30. North America Pharmacokinetics Services Market Breakdown, by Key Countries, 2023 and 2031 (%)
Figure 31. United States: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 32. Canada: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million)
Figure 33. Mexico: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million)
- Charles River Laboratories International Inc
- Eurofins Scientific SE
- Evotec SE
- Certara Inc.
- Parexel International Corp
- Thermo Fisher Scientific Inc.
- Allucent
- PACIFIC BIOLABS
- SGS SA
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America pharmacokinetics services market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the North America pharmacokinetics services market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth North America market trends and outlook coupled with the factors driving the North America pharmacokinetics services market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.